专利检索 ap:("CHEMOMAB LTD.") AND inv:"Michal SEGAL SALTO" 第 1 页

1.

发明公开
CCL24 INHIBITORS IN THE TREATMENT OF COVID-19 审中-公开

公开(公告)号：US20230192836A1

公开(公告)日：2023-06-22

申请号：US17996120

申请日：2021-04-20

申请人： CHEMOMAB LTD.

发明人： Adi MOR , Arnon AHARON , Michal SEGAL SALTO , Neta BARASHI

IPC分类号： C07K16/24

CPC分类号： C07K16/24 , C07K2317/24

摘要： The invention concerns isolated monoclonal antibodies that bind to CCL24 (eotaxin 2) for use in the treatment of Covid-19.

2.

发明公开
METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY 审中-公开

公开(公告)号：US20230235037A1

公开(公告)日：2023-07-27

申请号：US17996386

申请日：2021-04-20

申请人： CHEMOMAB LTD.

发明人： Adi MOR , Arnon AHARON , Sharon HASHMUELI , Michal SEGAL SALTO , Neta BARASHI

IPC分类号： C07K16/24 , A61K47/26 , A61K47/18 , A61K9/00 , A61P1/16

CPC分类号： C07K16/24 , A61K47/26 , A61K47/183 , A61K9/0019 , A61P1/16

摘要： Provided are compositions and methods for treating fibrotic inflammatory diseases, including non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with an anti-CCL24 monoclonal antibody.